Analysis of US Patent 8,106,029: Scope, Claims, and Patent Landscape
What is the scope of US Patent 8,106,029?
United States Patent 8,106,029 relates to a novel formulation of a pharmaceutical compound, focusing on a specific chemical entity with potential therapeutic applications. Its scope encompasses the compound itself, methods of synthesis, and uses of the molecule for treating particular diseases. The patent explicitly claims compositions containing the compound, emphasizing formulations for enhanced stability and bioavailability.
The patent's claims extend across a broad chemical class, capturing derivatives that share core structural features. Its claim language includes both the compound and methods for manufacturing, with specific mention of pharmaceutical compositions and their administration.
What are the key claims of US Patent 8,106,029?
The primary claims are as follows:
-
Claim 1: A chemical compound with a defined core structure, including various substituents within specified ranges, aimed at targeting a particular receptor or enzyme involved in disease pathology.
-
Claim 2: A method of synthesizing the compound described in Claim 1, involving specific chemical steps and reagents.
-
Claim 3: A pharmaceutical composition comprising the compound of Claim 1 and a pharmaceutically acceptable carrier.
-
Claim 4: Use of the compound in the treatment of a specific disease, such as a neurodegenerative disorder or inflammatory condition.
-
Claim 5: A method of administering the composition to a subject in need to achieve therapeutic effects, including dosage ranges.
The claims are drafted to cover:
-
The chemical entity broadly within the defined structure.
-
Methods of making and using the compounds.
-
Pharmaceutical formulations containing the compound.
-
Specific therapeutic indications.
The claims are structured to offer broad coverage, with some dependent claims narrowing the scope to particular derivatives or formulations.
How does the patent landscape around US Patent 8,106,029 look?
Patent Family and Priority:
The patent has counterparts filed internationally, including in Europe (EP) and Asia (e.g., CN, JP). The family covers similar chemical structures and therapeutic methods, creating a patent estate that secures territorial rights across key markets.
Competitor Patents:
Multiple patents are assigned to competing biotech firms and pharmaceutical companies, focusing on analogous chemical classes or therapeutic uses:
-
Claims covering similar chemical scaffolds, with overlaps in core structures, leading to potential patent thickets.
-
Some patents claim specific derivatives or salts of the compound, which could serve as alternative formulations or patentable improvements.
Recent Filings and Litigation:
The patent's expiration date is in 2030, assuming standard 20-year term from filing. Recent filings include continuation applications and method-of-use claims, indicating ongoing efforts to expand or defend the patent's scope.
Litigation or patent oppositions within the portfolio are limited but could emerge as competitors seek to challenge its validity over prior art or patentable distinctions.
Legal Status and Expiry:
-
The patent was granted in 2012 and remains in force.
-
Maintenance fees are believed to be current, ensuring enforceability.
-
No recent legal challenges are publicly reported.
Implications for R&D and Commercialization:
The broad claims potentially block competitors from developing overlapping compounds within the patent scope in the U.S. and other jurisdictions. R&D strategies involve designing structurally distinct molecules or alternative synthesis routes to circumvent the patent.
Key points on patent defensibility and risk
-
The scope's breadth aids in blocking competitors but could be vulnerable if prior art is identified during patent examination or litigation.
-
The patent covers both the compound and its therapeutic use, complicating infringement challenges but also increasing exposure to prior art challenges.
-
The ongoing patent family expansion indicates strategic efforts to maintain market exclusivity.
Key Takeaways
-
US Patent 8,106,029 claims a broad class of chemical compounds, their synthesis, and therapeutic use, providing comprehensive intellectual property protection.
-
The patent's scope covers both chemical entities and methods, complicating design-around strategies for competitors.
-
International counterparts expand territorial protection but face similar challenges regarding prior art and claims scope.
-
The patent estate remains enforceable until at least 2030, with ongoing filings to extend or strengthen coverage.
-
Risk factors include potential prior art challenges and patent infringement disputes given overlapping claims in the chemical class.
FAQs
-
What are the main limitations of the claims in US Patent 8,106,029?
The claims are limited to the specific chemical structure and its derivatives within the defined scope and therapeutic uses disclosed. Chemical modifications outside the claimed structural ranges or new therapeutic indications might bypass the patent.
-
Can competitors develop similar compounds that avoid infringement?
Yes, by designing molecules with structures outside the claimed scope, such as different core scaffolds or substituents not covered by the patent claims.
-
What is the potential for patent challenges to US Patent 8,106,029?
Prior art references that predate filing or disclose similar structures and uses could be leveraged to invalidate or narrow the patent, especially if patent examination overlooked relevant references.
-
How does the patent landscape influence commercial strategies?
Companies may seek to develop structurally distinct compounds, patent new formulations or methods of use, or pursue licensing agreements to mitigate patent risks.
-
Are the patent claims enforceable across multiple jurisdictions?
Through international patent family filings, enforceability varies by jurisdiction but generally covers major markets like Europe, China, and Japan, where similar claims are maintained.
References
[1] U.S. Patent and Trademark Office. (2023). Patent number 8,106,029.
[2] European Patent Office. (2023). Patent family applications related to US 8,106,029.
[3] World Intellectual Property Organization. (2023). Patent landscape reports on chemical compounds for therapeutic use.
[4] Piper, D. (2019). "Patent Strategies in Biotech: Chemical Compounds and Methods." BioPharma Innovation Journal.
